scholarly journals Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data

Haemophilia ◽  
2016 ◽  
Vol 23 (1) ◽  
pp. 50-58 ◽  
Author(s):  
K. Amano ◽  
I. Seita ◽  
S. Higasa ◽  
A. Sawada ◽  
M. Kuwahara ◽  
...  
Keyword(s):  
Surveillance Data ◽  
Factor Vii ◽  
Haemophilia A ◽  
Postmarketing Surveillance ◽  
Recombinant Activated Factor Vii ◽  
Acute Bleeding ◽  
Acquired Haemophilia ◽  
Activated Factor Vii

scholarly journals Acquired Haemophilia A. Which is the best therapeutic choice in older adults? Single center study of 4 cases

Reumatismo ◽  
2019 ◽  
Vol 71 (1) ◽  
pp. 37-41 ◽  
Author(s):  
E. Mauro ◽  
E. Garlatti Costa ◽  
A. Zanier ◽  
M. Maset ◽  
A. Ermacora ◽  
...  
Keyword(s):  
Coagulation Factor ◽  
Factor Vii ◽  
Haemophilia A ◽  
Recombinant Activated Factor Vii ◽  
Acquired Haemophilia ◽  
Activated Factor Vii ◽  
Activated Prothrombin Complex Concentrate ◽  
Therapeutic Choice ◽  
Single Center Study ◽  
Thrombotic Complications

Acquired haemophilia A (AHA) is a rare bleeding disorder due to autoantibodies directed against coagulation factor VIII. The treatment is based on recombinant activated factor VII and activated prothrombin complex concentrate. However, mainly in older patients, severe thrombotic complications have been reported. Here we report the different therapeutic approaches in 4 cases of elderly patients with AHA and co-morbidities.

scholarly journals Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: Results from a prospective study (ACQUI-7) in France

2021 ◽  
Vol 2 ◽  
pp. 100021
Author(s):  
Benoît Guillet ◽  
Achille Aouba ◽  
Annie Borel-Derlon ◽  
Jeanne Yvonne Borg ◽  
Jean-François Schved ◽  
...  
Keyword(s):  
Prospective Study ◽  
Factor Vii ◽  
Haemophilia A ◽  
Recombinant Activated Factor Vii ◽  
Acquired Haemophilia ◽  
Activated Factor Vii ◽  
A Prospective Study

scholarly journals Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A

2017 ◽  
Vol 8 (9) ◽  
pp. 263-272 ◽  
Author(s):  
Emma Fosbury ◽  
Anja Drebes ◽  
Anne Riddell ◽  
Pratima Chowdary
Keyword(s):  
Treatment Algorithm ◽  
Individual Variability ◽  
Response To Treatment ◽  
Factor Vii ◽  
Fixed Dose ◽  
Haemophilia A ◽  
Recombinant Activated Factor Vii ◽  
Acquired Haemophilia ◽  
Activated Factor Vii ◽  
Activated Prothrombin Complex Concentrates

Acquired haemophilia A (AHA) is a rare, serious bleeding disorder most often encountered in elderly patients. The mainstay of haemostatic management is with bypassing agents (BPAs) including recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCCs). Their major limitation is incomplete efficacy, potential risk for thrombosis and the lack of routine laboratory assays for monitoring treatment response. Plasma-derived porcine FVIII (pd-pFVIII, Hyate C®), first used in the 1950s for the management of congenital haemophilia, has sufficient sequence homology to be haemostatic in humans, but the lack of complete homology facilitates efficacy even in the presence of human allo- and autoantibodies against human FVIII (hFVIII). In a small phase II/III study, recombinant porcine FVIII (rpFVIII, Obizur®, OBI-1, susoctocog alfa) was shown to be safe and effective for the management of bleeding episodes in patients with AHA with anti-porcine FVIII (anti-pFVIII) antibody levels of 20 BU/ml or less. Treatment outcome was judged on clinical response and FVIII levels after an initial fixed dose of 200 IU/kg. The rise in FVIII levels showed considerable inter-individual variability and was significantly influenced by the presence of anti-pFVIII antibodies. Based on the baseline levels of anti-pFVIII antibodies and response to treatment, three potential patient groups were identifiable. In the first group, the absence of cross-reacting antibodies was associated with supra-therapeutic FVIII levels, fewer infusions and lower rpFVIII utilization per treatment episode. The second group had patients with low levels of cross-reacting anti-pFVIII antibodies (0.8–5 BU/ml) with near-normal response to rpFVIII. The last group had higher titres of anti-pFVIII antibody (10–30 BU/ml) associated with lower FVIII levels, more infusions and higher consumption of rpFVIII. We propose a new treatment algorithm for the haemostatic management of AHA that includes the potential first-line clinical use of rpFVIII that takes into account availability of anti-pFVIII antibody results, titre of anti-pFVIII antibodies and severity of bleeding episode.

The use of recombinant activated factor VII in patients with acquired haemophilia

Blood Reviews ◽  
2015 ◽  
Vol 29 ◽  
pp. S19-S25 ◽  
Author(s):  
Andreas Tiede ◽  
Kagehiro Amano ◽  
Alice Ma ◽  
Per Arkhammar ◽  
Soraya Benchikh el Fegoun ◽  
...  
Keyword(s):  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Acquired Haemophilia ◽  
Activated Factor Vii

scholarly journals Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors

2016 ◽  
pp. 1
Author(s):  
Meriem Bensadok ◽  
Abdulkareem Almomen ◽  
Azzam Alzoebie ◽  
Soraya Benchikh el Fegoun ◽  
Yasser Wali ◽  
...  
Keyword(s):  
Home Treatment ◽  
Factor Vii ◽  
Haemophilia A ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii

Successful management of Mallory-Weiss syndrome in a haemophilia A patient with inhibitor by recombinant activated factor VII

Haemophilia ◽  
2008 ◽  
Vol 14 (4) ◽  
pp. 841-843 ◽  
Author(s):  
Y. UCHIDA ◽  
Y. SAKURAI ◽  
K. OGIWARA ◽  
T. CHIYONOBU ◽  
B. HIGUCHI ◽  
...  
Keyword(s):  
Factor Vii ◽  
Haemophilia A ◽  
Successful Management ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii
Sign in / Sign up

Export Citation Format

Share Document